Bob,
My suggestion would be to go. Don't be misled by the extravagant title of the meeting. Yes, that title will be the guiding force in the selection of plenary speakers. These talks will get you excited about things on the horizon and even though "Macromolecular Communications" doesn't sound like it will touch concerns of fragment analysis, it will. If you have ever seen a talk by David Schwartz (meeting co-chair) with his whole genome restriction digest movies you have to believe he'll have put some fragment analysis in somewhere.
But the meat and potatoes of an ABRF meeting are all of the other sessions. I believe the fragment analysis as well as other techniques concerning DNA are well represented and are continuing to become a larger part of the meeting.
I would find out the name of all the members of the fragment analysis research group (FARG) and e-mail them before the meeting and hunt them down during the meeting. Also grab the DNA sequencing group. They might not admit it but they all do some genotyping on the side.
Asking them to meet you at the bar will raise the interest of this group..
hope to see you there, Paul
-- ____________________________________ Paul Morrison JFB216 paul_morrison@dfci.harvard.edu Molecular Biology Core Facilities Dana-Farber Cancer Institute http://mbcf.dfci.harvard.edu 44 Binney Street 617-632-3082 Boston, MA 02115 fax 632-4814 ____________________________________Bob Keefe <keefe@wadsworth.org> wrote: > January 02, 2001 > >Hi Folks, > > This message is directed to persons who plan on attending, or are >thinking about attending the ABRF meeting next month. I've never attended >an ABRF meeting, and I'm trying to decide whether I should petition my >supervisor for the funding needed to go to San Diego in February. Judging >from the title of the meeting: "The New Biology: Technologies for >Resolving Macromolecular Communications", it appears that the focus of the >meeting will be in areas not directly related to DNA fragment >analysis/genotyping - which is the kind of work I'm presently involved >with. Therefore, I'm wondering whether attendance to this next meeting by >personnel in DNA/Fragment-related Cores will be low, or lower than if the >focus of the meeting were on genotyping-related, or DNA-based technology? >I ask because I could easily rationalize the expense of attending the >meeting to my boss if I was confident that it would be attended by a >significant number of folks doing genotyping work with whom I could discuss >issues relative to my own recent trials & tribulations while starting-up a >new Genomics/Genotyping Core here. If expected attendance this year by >Fragment Analysis-type folks will be lower than usual (due to the nature of >this year's meeting's focus), maybe I'll pass on attending this time, and >see how things look in 2002 (in Austin, right?). Any input/responses from >(potential) attendees would be appreciated. > >Happy New Year! > >Bob > > >Robert G. Keefe, Ph.D. >Wadsworth Center/NYS Dept. of Health >Genomics Core Facility
This archive was generated by hypermail 2b29 : Fri Jan 05 2001 - 08:42:46 EST